新股消息 海西新药二次递表港交所 双轨模式打造多元化产品组合及管线

Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. has submitted its application to the Hong Kong Stock Exchange for listing on the main board, with Huatai International and China Merchants International as joint sponsors. The company is in the commercialization stage and has a diverse product portfolio and pipeline in the rapidly growing therapeutic areas in China [1][2]. Company Overview - Haixi New Drug is a pharmaceutical company that integrates research and development, production, and sales capabilities, with a focus on both generic drugs and innovative drugs in its pipeline [1]. - The company has received approval from the National Medical Products Administration for 14 generic drugs and has established a pipeline of four innovative drugs under development [1]. Product and Market Focus - The company employs a dual-track model, focusing on both generic drugs and innovative drugs. Its generic drugs are characterized by significant technical barriers and market potential, with timely regulatory approvals [1]. - The innovative drug pipeline targets unmet medical needs and has substantial global market potential, including a potential first-in-class oncology drug and an oral drug for treating wAMD/DME/RVO [1]. Financial Performance - As of July 8, 2025, the company's commercialized product portfolio includes generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, which collectively account for over 25% of China's pharmaceutical sales in 2023 [2]. - The company's revenue from the top five customers has shown a decreasing trend from 85.1% in 2022 to 71.7% in the first five months of 2025 [2]. - Revenue figures for the years 2022, 2023, 2024, and the first five months of 2025 are approximately RMB 212 million, RMB 317 million, RMB 467 million, and RMB 249 million, respectively, with corresponding profits of approximately RMB 69 million, RMB 117 million, RMB 136 million, and RMB 90 million [2].